<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008952</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-20-339-STW</org_study_id>
    <nct_id>NCT05008952</nct_id>
  </id_info>
  <brief_title>Identification of Early Cardiovascular Disease Risk Factors in Normal-weight Obesity</brief_title>
  <official_title>Postprandial Triglycerides, Endothelial Function, and Inflammatory Cytokines as Potential Candidates for Early Risk Detection in Normal-weight Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oklahoma State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oklahoma State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify early cardiovascular disease risk factors in those&#xD;
      with &quot;normal-weight obesity&quot; (i.e., normal body, but high body fat percentage) that better&#xD;
      track with their long-term cardiovascular disease risk.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Actual">July 20, 2021</completion_date>
  <primary_completion_date type="Actual">July 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>3 study groups: control (normal body mass index, low body fat percentage), normal-weight obesity ((normal body mass index, high body fat percentage), and metabolic syndrome</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>4-hour triglycerides after fat tolerance test</measure>
    <time_frame>Within 2 weeks of study enrollment</time_frame>
    <description>Participants will undergo an abbreviated fat tolerance test, where fasting triglycerides are measured, a high-fat shake is consumed, and triglycerides measured once more 4 hours later. 4 hour triglycerides after the high-fat meal is our primary outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Flow-mediated dilation</measure>
    <time_frame>Within 2 weeks of study enrollment</time_frame>
    <description>Flow-mediated dilation is a non-invasive technique to investigate vascular health. This technique will be performed when participants are fasting and ~4 hours after the shake is completed (just before final measurement of triglycerides)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum cytokines</measure>
    <time_frame>Within 10 months of study enrollment</time_frame>
    <description>A number of cytokines including GM-CSF, IFN-gamma, IL-1beta, IL-2, IL-5, IL-6, IL-8, IL-12p70, IL-13, IL-17, TNF-alpha, IL-4, IL-10 will be measured as additional cardiovascular disease risk factors.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group for this study will consist of individuals with normal BMI (18.5 - 24.9 kg/m2), body fat percent &lt; 25% (male) or &lt; 35% (female), and up to 1 other risk factor among the following: blood pressure &gt; 130/85 mmHg, fasting glucose &gt;100 mg/dL, fasting triglycerides &gt;150 mg/dL, and HDL &lt; 40 (male) or &lt; 50 (female).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal-weight obesity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals with normal-weight obesity will be defined as having normal BMI (18.5 - 24.9 kg/m2), body fat percent &gt; 25% (male) or &gt; 35% (female).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metabolic Syndrome</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metabolic syndrome will be defined using the international Diabetes Federation criteria of an obese BMI ( &gt; 30 kg/m2) and 2 or more of the following risk factors: blood pressure &gt; 130/85 mmHg, fasting glucose &gt;100 mg/dL, fasting triglycerides &gt;150 mg/dL, and HDL &lt; 40 (male) or &lt; 50 (female).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High-fat shake</intervention_name>
    <description>All participants will be given a high-fat test meal to examine their postprandial triglyceride response.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Metabolic Syndrome</arm_group_label>
    <arm_group_label>Normal-weight obesity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Control group: normal BMI, body fat percentage &lt; 25% for men and 35% for women&#xD;
&#xD;
        Normal-weight obesity group: normal BMI, body fat percentage &gt; 25% for men and 35% for&#xD;
        women&#xD;
&#xD;
        Metabolic syndrome group: BMI &gt; 30 and 2 or more of the following: blood pressure &gt;130/85&#xD;
        mmHg, fasting glucose &gt;100 mg/dL, fasting triglycerides &gt;150 mg/dL, HDL cholesterol &lt; 40&#xD;
        mg/dL (men) or &lt; 50 mg/dL (women).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of pacemaker&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  use of tobacco products&#xD;
&#xD;
          -  using lipid lowering drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oklahoma State University</name>
      <address>
        <city>Stillwater</city>
        <state>Oklahoma</state>
        <zip>74078-6104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

